How to Prescribe Ceftazidime for UTI
For adults with complicated UTI, prescribe ceftazidime 2 grams IV every 8 hours for 7-14 days, adjusting the dose based on renal function and transitioning to oral therapy once clinically stable. 1
Dosing by Clinical Scenario
Standard Adult Dosing
- Uncomplicated UTI: 250 mg IV/IM every 12 hours 1
- Complicated UTI: 500 mg IV/IM every 8-12 hours OR 2 grams IV every 8 hours for severe infections 1
- Treatment duration: 7-14 days depending on severity 2
The FDA-approved dosing provides clear guidance: for most complicated UTIs, 500 mg every 8-12 hours is adequate, but reserve the 2-gram every 8-hour regimen for severe infections or immunocompromised patients 1.
Pediatric Dosing
For febrile infants 8-21 days old with UTI: Ampicillin 150 mg/kg/day divided every 8 hours PLUS ceftazidime 150 mg/kg/day divided every 8 hours (or gentamicin as alternative) 3
For infants 22-28 days old: Transition to ceftriaxone 50 mg/kg once daily is preferred over ceftazidime 3
For children 1 month-12 years: 30-50 mg/kg IV every 8 hours (maximum 6 grams/day) 2
The 2021 AAP guidelines specifically recommend ceftazidime combined with ampicillin for the youngest infants (8-21 days) to cover both Gram-negative organisms and Group B Streptococcus, but ceftriaxone becomes the preferred agent after 21 days of age 3.
Renal Dose Adjustments
Critical consideration: Ceftazidime is renally eliminated, requiring dose reduction in renal impairment to prevent neurotoxicity 1.
- CrCl 31-50 mL/min: 1 gram every 12 hours
- CrCl 16-30 mL/min: 1 gram every 24 hours
- CrCl 6-15 mL/min: 500 mg every 24 hours
- CrCl <5 mL/min: 500 mg every 48 hours 1
For hemodialysis patients: Give 1 gram loading dose, then 1 gram after each dialysis session 1
Important caveat: High ceftazidime levels can cause seizures, encephalopathy, myoclonus, and nonconvulsive status epilepticus in patients with renal impairment 1. Monitor closely and adjust doses promptly.
Route of Administration and Transition Strategy
Initial Parenteral Therapy
Start with IV/IM ceftazidime for:
- Patients unable to tolerate oral medications
- Severe infections requiring immediate high tissue concentrations
- Suspected bacteremia from urinary source 4
Transition to Oral Therapy
Switch to oral antibiotics when ALL of the following are met 4:
- Clinically improving (afebrile, hemodynamically stable)
- Able to take oral medications
- Effective oral option available based on susceptibilities
- Source control achieved (obstruction relieved if present)
The 2026 IDSA guidelines provide strong evidence that early transition to oral therapy (even in bacteremic UTI) is safe once patients meet these criteria, reducing catheter-related complications and costs 4.
Preferred oral step-down options (based on susceptibilities):
- Fluoroquinolones: Ciprofloxacin 500-750 mg every 12 hours or levofloxacin 750 mg daily 4
- Cephalosporins: Cefpodoxime 200-400 mg every 12 hours or cefixime 400 mg daily 4
- TMP-SMX: 800-160 mg every 12 hours (if susceptible) 4
Special Populations
Multidrug-Resistant Organisms
For carbapenem-resistant Enterobacterales (CRE): Ceftazidime-avibactam 2.5 g IV every 8 hours is preferred over ceftazidime alone 5
For Pseudomonas aeruginosa: Standard ceftazidime dosing (2 grams every 8 hours) is appropriate, but consider extended infusion (3-4 hours) for severe infections or augmented renal clearance 6, 7
Pregnancy and Catheter-Associated UTI
Ceftazidime is safe in pregnancy. For catheter-associated UTI, remove or replace the catheter when feasible before initiating therapy 8.
Common Pitfalls to Avoid
Don't use ceftazidime monotherapy for febrile infants <21 days old - must combine with ampicillin for enterococcal and GBS coverage 3
Don't forget renal dose adjustments - failure to reduce doses in renal impairment can cause serious neurotoxicity including seizures 1
Don't use standard infusion times for severe Pseudomonas infections - consider extended 3-4 hour infusions or continuous infusion for optimal PK/PD targets 6
Don't continue IV therapy longer than necessary - transition to oral once stable to reduce line complications 4
Monitor for resistance development - particularly with Enterobacter, Pseudomonas, and Serratia species which can develop inducible resistance during therapy 1